Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776141 | 0.94 | TRPV1 (0.37) | TRPV1 | |
| Trifluoroacetic Acid SCHEMBL5772877 | 0.76 | HTT (0.39) | KDM4EMEN1KMT2A | |
| SCHEMBL5777440 | 0.75 | HDAC8 (0.35) | HDAC8HCRTR1HCRTR2KDM4ESMN1; SMN2 | |
| SCHEMBL5771833 | 0.75 | DRD2 (0.42) | KDM4E | |
| SCHEMBL5775533 | 0.74 | HDAC8 (0.33) | HDAC8 | |
| SCHEMBL5773350 | 0.74 | TSHR (0.40) | ALDH1A1 | |
| SCHEMBL5774897 | 0.74 | MPO (0.35) | HDAC8ALDH1A1KMT2A | |
| SCHEMBL5773778 | 0.74 | PLA2G7 (0.36) | HDAC8KCNH2KDM4EALDH1A1 | |
| SCHEMBL5771067 | 0.73 | HDAC8 (0.35) | HDAC8 | |
| SCHEMBL5775799 | 0.73 | HDAC8 (0.34) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | HDAC8 639/4885HCRTR1 284/4885HCRTR2 269/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | HDAC8 569/4885HCRTR1 965/4885HCRTR2 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.